ENTA · Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals reported financial results for its fiscal second quarter ended March 31, 2026, showing a narrower net loss compared to the prior year. Total revenue increased to $17.2 million from $14.9 million, driven by higher royalty revenue from AbbVie's HCV drug MAVYRET/MAVIRET. Research and development expenses decreased to $19.4 million from $28.1 million, primarily due to lower clinical trial costs for RSV programs, partially offset by increased immunology spending. General and administrative expenses fell to $9.6 million from $11.4 million, mainly due to lower stock-based compensation. Interest expense rose to $3.3 million from $1.7 million, reflecting higher royalty revenue. Net loss improved to $13.1 million ($0.45 per share) from $22.6 million ($1.06 per share). The company ended the quarter with $227 million in cash and marketable securities, expected to fund operations into fiscal 2029. Management highlighted key pipeline milestones: dosing initiated in a Phase 1 trial of EDP-978 (oral KIT inhibitor for chronic urticaria), with topline data expected in Q4 2026; IND filing for EPS-3903 (STAT6 inhibitor) and MRGPRX2 candidate selection on track for H2 2026; and enabling activities for a pivotal study of zelicapavir in high-risk RSV patients, with an update expected in Q2 2026. The company also noted ongoing litigation against Pfizer regarding PAXLOVID patent infringement, with a Federal Circuit decision anticipated by September 2026.